Exopharm Limited (EX1) TRADING HALT SUSPENDED

20mins delayed

Movement

1 Year Return

System message

20 June 2019: Highest Dividend Yield stocks and ASX Broker Consensus scans updated. Join my email list to get notified.

Exopharm Limited Chart

Share price
Last
Change
Volume
Turnover
Market Cap $17.71 million
Today's Movement
Prev. Close
Open
Day Range -
VWAP
Historical Stats
52w Range -
4w Avg Volume
4w Avg Turnover
(delayed)

EX1 Statistics

26 June

1,467 / 2,323

ASX Size Rank

1yr Return

vs Sector (1yr)

-29.00%

vs ASX 200 (1yr)

-26.38%

$17.71 million

Market Cap

Share Issue

42.16 million

All Ords (%)

N/A

Short Sold

0%

Current Fundamentals

26 June

N/A

PE Ratio

EPS ($)

-0.019

Earnings Yield

-4.43%

NTA ($)

0.08

N/A

Dividend Yield

DPS ($)

-

Gross Div. Yield

-

Gross DPS ($)

-

Company Overview

Exopharm Limited (EX1) operates in the healthcare sector, specifically in the regenerative medicine industry. As its primary focus, Exopharm aims to be a leader in the field of clinical human therapeutics using exosomes as regenerative medicine products. Exopharm seeking to develop and commercialise exosomes as therapeutic agents – initially a product called Plexaris and later as a product called Exomeres. These products are exosomes that are derived from human platelets in relation to Plexaris, and adult stem cells in relation to Exomeres, and purified using the LEAP Technology and referred to as biologic products. Exopharm's key asset is the LEAP Technology (which includes the Patent Applications) and associated know-how.

Exopharm Limited Logo

Corporate Details

Head Office: Melbourne
Managing Director: Ian Dixon
GICS Sub-Industry: Biotechnology
Date Listed: 18 Dec 2018
Registry: Automic
Similar Companies: CSL / SRX / MSB / CUV / VLA

Upcoming Calendar

Dividend History

Ex-Date Amount Franking Type Payable
No dividends paid in the last 5 years

See Upcoming Dividends for all ASX companies.

Announcements

Date Heading Pages File Size Time

Broker Consensus

The buy, hold and sell recommendations from Australian stockbroking firms are combined to form a "broker consensus". See the Consensus Data posts for more information.

EX1 is not covered by a major broker.

Directors & Management

About the Data


Name Title Since Bio
Mr David Rodney Parker Company Secretary, Non-Executive Director Jun 2018
Dr Ian Edward Dixon Company Founder, Technology Co-Founder, Managing Director May 2013
Mr Jason Mark Watson Non-Executive Chairman, Non-Executive Director Aug 2018

Director Transactions

About the Data

EX1 directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

There are no director transactions for code EX1 in our database.

Shareholder Distribution

Shareholder Distribution data is unavailable.

Top 20 Shareholders

About the Data

Name Shares Capital
Altnia Holdings Pty Ltd 27,935,294 34.70%
Mr Michael Francis Mcmahon & Mrs Susan Lesley Mcmahon 2,385,000 2.96%
Oldview Enterprises Pty Ltd 1,345,834 1.67%
Anthony John Locantro 1,330,000 1.65%
Citicorp Nominees Pty Limited 1,250,000 1.55%
Phytose Corporation Pty Ltd 1,176,471 1.46%
Pabasa Pty Ltd 1,000,000 1.24%
Carda Pty Ltd 965,000 1.20%
Mrs Anna Felicia Belton 920,833 1.14%
Basapa Pty Ltd 750,000 0.93%
Drp 2006 Super Pty Ltd 740,000 0.92%
Sunshine Group Investments Pty Ltd 700,000 0.87%
Lonhro (WA) Pty Ltd 686,667 0.85%
Saintly Company Pty Ltd 680,000 0.84%
ACNS Capital Markets Pty Ltd 667,800 0.83%
Mr Andrew Stewart Coles & Ms Alexandra Constancemanook 625,000 0.78%
Gregor Lichtfuss 588,235 0.73%
Jecss Pty Ltd 500,000 0.62%
Labonne Enterprises Pty Ltd 500,000 0.62%
Aukera Capital Pty Ltd 500,000 0.62%
Mr Craig Ian Brown & Mrs Jenny Lee Brown 500,000 0.62%
Brisque Pty Ltd 500,000 0.62%
Kohen Enterprises Pty Ltd 500,000 0.62%
Ringsford Pty Ltd 475,000 0.59%
GAIL Garrity Pty Ltd 408,666 0.51%
All other shareholders 40.86 %


The Top 20 Shareholders of EX1 hold 59.14% of shares on issue.

EX1 Share Price History

Date Close Change % Change Open High Low Volume Turnover

EX1 Historical Data

Download up to 20 years of share price history.


Year Closing Price (30 June) Last Trade

Offical data as published by ASX. See more Data Downloads.

Company Details

Principal Activity: Biopharmaceutical research with a primary focus on developing and commercialising exosomes as therapeutic agents.

Incorporated: --

Level 17, 31 Queen St
Melbourne VIC 3000


All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.